On November 5, 2025, argenx SE announced that Health Canada approved VYVGART SC (efgartigimod alfa injection) as a monotherapy for adults with active chronic inflammatory demyelinating polyneuropathy ...

Dr. Lin joins Nuvig to advance NVG-2089 through Phase 2 studies in chronic inflammatory demyelinating polyneuropathy and ...

The good news is that, with significant late-stage pipeline activity, new early-stage projects, and continued strong ...

HK Innoen is accelerating the expansion of its portfolio in geriatric and metabolic diseases by launching full-scale development of a treatment for ...

Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive ...

Immunovant remains on track for the first of the two batoclimab Phase 3 thyroid eye disease (TED) studies to read out before the end of calendar year 2025. However, due to evolving competitive ...

The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Read more ...

The thought 'no-one is accountable' for the death of Helen Holland, the 81-year-old hit by the Duchess of Edinburgh's royal ...

The hybrid CME/CE event featured expert sessions on neurological disorders, emerging technologies, and evidence-based care, strengthening the knowledge and skills of clinicians across the neurology ...

CNW/ - argenx SE (EURONEXT: ARGX) (Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Health Canada ...

Hummelstown native and three-decade Little League football coach Steve Messick was enjoying Super Bowl LIX in February when ...

Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and other ...